A Study of IBI3046 in Participants With Overweight or Obesity

Inclusion Criteria: * 1.Aged between 18 and 65 years (inclusive) at the time of informed consent, male or female; * 2.At screening, 24 kg/m² ≤ BMI ≤ 40 kg/m²; * 3.Body weight change ≤ 5 % within 3 months prior to screening ; * 4.Female participants of child bearing potential and male participants whose partners are of child bearing potential must agree to use highly effective contraceptive methods during the study and for 6 months after the last study drug administration. For female participants of child bearing potential, the pregnancy test result must be negative at screening. Female participants shall not breast feed. Male / female participants must be willing to refrain from sperm / oocyte donation during the study and for 6 months after the last study drug administration; * 5.Able to understand study procedures and requirements, willing to strictly comply with the clinical trial protocol, and voluntarily sign the informed consent form. Exclusion Criteria: * 1\. Secondary overweight or obesity caused by drugs, genetic or other systemic diseases. * 2\. Abnormal glucose metabolism, including diabetes history or clinically significant abnormal glycemic indicators at screening. * 3\. Clinically significant abnormal liver function, hematological parameters, ECG indicators or vital signs at screening. * 4\. Positive screening results for infectious pathogen markers. * 5\. Personal or family history of specific thyroid neoplasms or endocrine disorders, or clinically significant abnormal thyroid function and thyroid lesions at screening. * 6\. History of pancreatitis, severe lipid metabolism disorders, severe hypoglycemia or diabetic ketoacidosis. * 7\. Presence of untreated or clinically significant systemic organ diseases, mental disorders or suicidal risk. * 8\. History of malignant tumors (excluding partial skin cancers) within 5 years. * 9\. Positive screening results for infectious pathogen markers. * 10\. Personal or family history of specific thyroid neoplasms or endocrine disorders, or clinically significant abnormal thyroid function and thyroid lesions at screening. * 11\. History of pancreatitis, severe lipid metabolism disorders, severe hypoglycemia or diabetic ketoacidosis. * 12\. Presence of untreated or clinically significant systemic organ diseases, mental disorders or suicidal risk. * 13\. History of malignant tumors (excluding partial skin cancers) within 5 years.